بدائل البحث:
non decrease » nn decrease (توسيع البحث), point decrease (توسيع البحث), note decreased (توسيع البحث)
we decrease » _ decrease (توسيع البحث), nn decrease (توسيع البحث), teer decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
e non » _ non (توسيع البحث), a non (توسيع البحث)
5 we » _ we (توسيع البحث), 5 wt (توسيع البحث), 5 w (توسيع البحث)
non decrease » nn decrease (توسيع البحث), point decrease (توسيع البحث), note decreased (توسيع البحث)
we decrease » _ decrease (توسيع البحث), nn decrease (توسيع البحث), teer decrease (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
e non » _ non (توسيع البحث), a non (توسيع البحث)
5 we » _ we (توسيع البحث), 5 wt (توسيع البحث), 5 w (توسيع البحث)
-
201
-
202
-
203
-
204
Advancing the science of NOWS research.
منشور في 2024"…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …"
-
205
Protocol measures.
منشور في 2024"…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …"
-
206
Cry variables.
منشور في 2024"…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …"
-
207
DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf
منشور في 2022"…However, the continuous virus evolution requires diverse mAb options to combat variants. Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …"
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
The raw data for Fig 5B.
منشور في 2025"…This study applied the new method to <i>Sox10</i>, uncovering two OL enhancers for it (termed Sox10-E1 and Sox10-E2). Epigenome editing analysis revealed that Sox10-E1 and Sox10-E2 regulate <i>Sox10</i> expression non-redundantly. …"
-
220